Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Guillain-Barre Syndrome Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Guillain-Barre Syndrome Overview | 7 | 1 |
| Pipeline Products for Guillain-Barre Syndrome Comparative Analysis | 8 | 1 |
| Guillain-Barre Syndrome Therapeutics under Development by Companies | 9 | 1 |
| Guillain-Barre Syndrome Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Guillain-Barre Syndrome Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Guillain-Barre Syndrome Products under Development by Companies | 14 | 1 |
| Guillain-Barre Syndrome Products under Investigation by Universities/Institutes | 15 | 1 |
| Guillain-Barre Syndrome Companies Involved in Therapeutics Development | 16 | 5 |
| Akari Therapeutics, Plc | 16 | 1 |
| CuraVac, Inc. | 17 | 1 |
| Hansa Medical AB | 18 | 1 |
| Regenesance BV | 19 | 1 |
| Vitality Biopharma Inc | 20 | 1 |
| Guillain-Barre Syndrome Therapeutics Assessment | 21 | 9 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 12 |
| Coversin Drug Profile | 30 | 3 |
| immune globulin (human) Drug Profile | 33 | 1 |
| Peptide for Cholera and Guillain-Barre Syndrome Drug Profile | 34 | 1 |
| Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders Drug Profile | 35 | 4 |
| Small Molecule to Inhibit C6 for Guillain-Barre Syndrome Drug Profile | 39 | 1 |
| Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders Drug Profile | 40 | 1 |
| Vaccine for Guillain-Barre Syndrome Drug Profile | 41 | 1 |
| Guillain-Barre Syndrome Dormant Projects | 42 | 1 |
| Guillain-Barre Syndrome Product Development Milestones | 43 | 4 |
| Featured News &Press Releases | 43 | 1 |
| May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barre Syndrome | 43 | 1 |
| May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barre Syndrome | 43 | 1 |
| Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines &Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial | 44 | 1 |
| Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays | 44 | 1 |
| Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting | 45 | 2 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |